Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose Ezetimibe in Homozygous Sitosterolemia
NCT00099996Phase 3Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Dec 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ezetimibe in sitosterolemia (2 arms), sponsored by National Heart, Lung, and Blood Institute. Primary endpoints: Plasma sitosterol concentration at 26 weeks and Plasma campesterol concentration at 26 weeks. Started Dec 2004; status: completed.
02
Drugs
ezetimibe
03
Conditions
sitosterolemia
Beyond the preview
Go deeper on NCT00099996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00099996.